<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631459</url>
  </required_header>
  <id_info>
    <org_study_id>KLT-2018</org_study_id>
    <nct_id>NCT03631459</nct_id>
  </id_info>
  <brief_title>A Multicenter Real World Study of Kanglaite for Cancer Cachexia</brief_title>
  <official_title>Safety and Effectiveness of Kanglaite Injection/Capsules for Treatment of Cancer Cachexia: A Prospective, Multicenter Real World Study of a Large Cohort of Chinese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Kanglaite Pharmaceutical Co.Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NanJing PLA 81 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LinkDoc Technology (Beijing) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Kanglaite Pharmaceutical Co.Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-center real-world study of the effectiveness and safety of Kanglaita
      Injection/Capsule in Chinese patients with cancer cachexia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a large national-based prospective, multi-center real-world observational study.
      Cancer cachexia patients scheduled for sequential treatment with Kanglaite injection and
      capsule between August 2018 and March 2020 at 640 participating hospitals will be recruited
      to evaluate the effectiveness and safety of Kanglaite.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 20, 2018</start_date>
  <completion_date type="Anticipated">July 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2018 - 2020</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lean body mass</measure>
    <time_frame>2018 - 2020</time_frame>
    <description>Lean body mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>2018 - 2020</time_frame>
    <description>Body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of cachexia</measure>
    <time_frame>2018 - 2020</time_frame>
    <description>Grade of cachexia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30</measure>
    <time_frame>2018 - 2020</time_frame>
    <description>European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30: 30 items, including functioning, symptoms, and overall health. min: 0, max: 100. The higher values indicate higher level of functioning and quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky performance status</measure>
    <time_frame>2018 - 2020</time_frame>
    <description>Karnofsky performance status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-generated subjective global assessment (PG-SGA)</measure>
    <time_frame>2018 - 2020</time_frame>
    <description>Patient-generated subjective global assessment (PG-SGA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale for pain</measure>
    <time_frame>2018 - 2020</time_frame>
    <description>Numeric rating scale for pain min: 0; max: 10. The higher values indicate worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale for appetite</measure>
    <time_frame>2018 - 2020</time_frame>
    <description>Numeric rating scale for appetite min: 0; max: 10. The higher values indicate worse appetite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Synergistic antitumor effect: Overall response rate</measure>
    <time_frame>2018 - 2020</time_frame>
    <description>Synergistic antitumor effect: Overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Synergistic antitumor effect: Disease control rate</measure>
    <time_frame>2018 - 2020</time_frame>
    <description>Synergistic antitumor effect: Disease control rate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>2018 - 2020</time_frame>
    <description>Adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Serious adverse event</measure>
    <time_frame>2018 - 2020</time_frame>
    <description>Serious adverse event</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100000</enrollment>
  <condition>Cancer Cachexia</condition>
  <arm_group>
    <arm_group_label>Kanglaite Injection/Capsules</arm_group_label>
    <description>Kanglaite injection 200ml, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kanglaite Injection/Capsules</intervention_name>
    <description>Kanglaite injection 200 mL, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles</description>
    <arm_group_label>Kanglaite Injection/Capsules</arm_group_label>
    <other_name>Coicis oil injection, Z10970091</other_name>
    <other_name>Coix seed oil triglyceride, 03004812Z</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients meeting international diagnostic criteria for cachexia:

          1. Weight loss &gt; 5% over past 6 months or

          2. BMI&lt;20 kg/m2 and weight loss &gt; 2% or

          3. Sarcopenia and weight loss &gt;2%;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with pathological or cytological diagnosis of lung, liver, pancreatic or stomach
        cancer; Patients scheduled to receive Kanglaite injection for 7 or more days, followed by
        Kanglaite capsule for 14 or more days; Patients willing to participate in this study and
        provide written informed consent.

        Exclusion Criteria:

        None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shukui Qin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NanJing PLA 81 Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shukui Qin, MD</last_name>
    <phone>0086-025-84453932</phone>
    <email>qinsk@csco.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University International Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102206</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Liang, MD</last_name>
      <phone>+86-010-69006900</phone>
      <email>liangjun1959@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NanJing PLA 81 Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shukui Qin, MD</last_name>
      <phone>+86-025-84453932</phone>
      <email>qinsk@csco.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>August 17, 2018</last_update_submitted>
  <last_update_submitted_qc>August 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kanglaita Injection/Capsule</keyword>
  <keyword>Cancer cachexia</keyword>
  <keyword>Real-world evidences</keyword>
  <keyword>Overall survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

